PYC-001

N/A

Report date: 2025/05/15 20:00:08
NME

Base Information

Drug NamePYC-001
Drug Alias NamePYC-001
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionAnti-Vascular endothelial growth factorRNA interference
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic RetinopathyOptic Atrophy, Autosomal DominantOptic Atrophies, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPYC Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesPYC Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsDiabetic RetinopathyOptic Atrophy, Autosomal DominantOptic Atrophies, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A